- Circassia Pharmaceuticals has completed recruitment into the pivotal phase III study of its cat allergy treatment, Cat-SPIRE.

When recruitment closed on 31 December, 1,409 subjects had been randomised into the study.

The total recruited exceeds the minimum target of 1,182, and includes an additional 91 subjects enrolled at centres in Russia to support a potential filing in this significant market.

The study is progressing as planned, and the company remains on track to report the results in H1 2016.

Chief executive Steve Harris said: "Our phase III Cat-SPIRE study is designed to efficiently assess our treatment in subjects who would benefit most from an effective new therapy. The team has made great progress in completing enrolment as planned into this international field study. We continue to be well placed to meet our timelines to complete the study in H1 2016, and, subject to the results, to file for regulatory approval later the same year."

At 8:22am: [LON:CIR] Circassia Pharmaceuticals Plc Ord 0.08p share price was +2.13p at 274.13p

Story provided by